Atherothrombosis and Coronary Artery Disease
Integrated basic and clinical research to study the etiology, pathogenesis, prevention, diagnosis, and treatment of CAD and atherothrombosis; translation of promising scientific and technological advances from discovery through preclinical studies to networks and multisite clinical trials.
Program Officers
Jue Chen, M.B., M.S., Ph.D.
Acting Deputy Branch Chief, Aging biology; Pharmacology and toxicology
301-435-0532
Jerome Fleg, M.D.
Clinical cardiovascular disease; Exercise physiology
301-435-0420
Ahmed A.K. Hasan, M.D., Ph.D.
Pharmacogenomics; Functional genomics; Inflammation; Anti-thrombotic agents
301-435-0064
Ruth Kirby, R.N., B.S.
Clinical trial management/operations; Autoimmune and cardiovascular diseases
301-435-0401
Martin Playford, Ph.D.
Inflammation; Translational research; Cell and molecular biology
301-827-3716
David Schopfer, M.D., M.A.S.
Clinical cardiovascular disease; Coronary artery disease
301-402-3833